Blue Note Therapeutics

Prescription digital therapeutics company.

Based in CA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $150K in lobbying spend across 6 quarterly filings, Blue Note Therapeutics is an active lobbying client. Their lobbying covers 1 issue area. Active from 2022 to 2023.

$150K
Total Spend
2
Years Active
1
Firms Hired
2
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2022$90K
2023$60K

Issues Lobbied

Medicare/Medicaid

Lobbying Firms

Todd Strategy Group

Lobbyists

Paul EdattelJeff Lucas

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid

  • •FDA User Fee Regulations.
  • •FDA User Fee Regulations. H.R.4128 - VALID Act of 2021.
  • •FDA User Fee Regulations. Reimbursement policy for prescription digital therapeutics.
  • •Reimbursement policy for prescription digital therapeutics.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Kaiser Foundation Health Plan INC
$31.5M total spend
Jazz Pharmaceuticals, INC.
$11.5M total spend
Biomarin Pharmaceutical INC.
$9.6M total spend
Acadia Pharmaceuticals
$7.3M total spend
Sarepta Therapeutics, INC.
$6.3M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.